The FLOW trial (Perkovic et al, NEJM 2024) was a phase 3 randomized trial, of 3,533 patients with type 2 diabetes and CKD (eGFR 50-75ml/min or 25-50 ml/min with albuminuria) who received 1 mg of subcutaneous semaglutide weekly, or placebo
Phc hi hng ro bo v da, kch thch ti to da, loi b tnh trng xn mu
AOD 9604 was actually developed far enough to go through human clinical trials for obesity treatment
Although serious adverse effects are uncommon, infants should be monitored if the medication is used during breastfeeding
Microdosing GLP-1 in menopause and perimenopause offers a gentle, strategic way to support your metabolism, appetite, and focus without the intensity or side effects that can come with higher doses
This approach supports long-term studies while maintaining solution integrity